EU Stakeholders Want More Focus On Availability Of Medicines
Consultation Comments Also Highlight Transparency And Supply Chain Concerns
EU regulators have released their medicines network strategy to 2025 following a consultation that revealed broad support for its aim of ensuring the continued availability of medicines and accelerating innovation, but flagged up a number of areas where respondents wanted more clarity.
You may also be interested in...
The coordination group for EU mutual recognition and decentralized procedures is inviting stakeholder feedback on its priorities for the coming years.
Days before the EU Clinical Trial Regulation is set to come into effect, a new initiative has been launched to track and support its successful implementation and help deliver other trial-related reforms.
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.